bioAffinity Technologies' noninvasive diagnostic shifted the course of care from watchful waiting to immediate treatment
CyPath® Lung identified cancer in a patient with ground-glass lung nodules
The technology provides actionable results that can lead to potentially life-saving treatment
CyPath® Lung Technology
Utilizes advanced flow cytometry and AI to identify malignancy indicators in patient sputum.
Clinical Efficacy
Demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients.
Real-World Application
Case study showed CyPath® Lung's value in providing actionable information for timely treatment decisions.
- CyPath® Lung offers clarity in evaluating indeterminate lung nodules
- The technology reduces uncertainty, potentially improving patient outcomes
CyPath® Lung's success in identifying lung cancer early highlights its potential to transform patient care and outcomes in the field of noninvasive diagnostics.